Search Results

The Triangle of Influence: Science, Market, and Money 👉 Every biotech startup operates within a triangle authority over scientific direction, commercial pivots, and fundraising strategy? 👉 By this point, you might be asking yourself: how much of our strategy is truly founder-led? start designing a strategy on purpose. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

A thoughtful patent strategy review early in the year allows biotech CEOs to realign intellectual property Turning Patent Strategy Review Into a Leadership Habit For many biotech companies, patent discussions growth instead of reacting to it . Smart biotech CEOs understand that strategy is not a document. . ✅ Revisiting patent strategy regularly allows leadership to guide growth with intention rather than

Most biotech startups get stuck proving potential. That one sentence explains why so many brilliant biotech startups stall before they ever reach the market , traction-focused biotech commercialization strategy looks like, without hiring a whole BD team or What a Real Biotech Commercialization Strategy Looks Like Most biotech founders think commercialization Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

It weakens when science and strategy are no longer part of the same decisions. But science and strategy are no longer shaping those decisions together. 👉 This disconnect usually starts When science and strategy disconnect early, alignment becomes a matter of luck. 👉 And execution starts It is a strategic choice. When science and strategy disconnect, collaboration weakens. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

Strong biotech licensing isn’t about validation; it’s about the discipline to protect your future degrees It shows up when founders treat biotech licensing like a moment of validation instead of a strategic A Simple Framework: The Three Levers of Licensing Strategy Think of your licensing agreement as three Strategic Takeaway – Clean Biotech Licensing 👉 The hard truth: Investors don’t just invest in science Attila runs focused strategy consultations for biotech founders who are ready to lead with clarity, not

But here’s the truth: AI is not a strategy.  It's a tool. "AI in biotech strategy: Use it as a tool, not a crutch" The Reality of AI in Biotech Strategy Let’s “AI in biotech strategy only creates value when it's aligned with your scientific and business milestones But unless you’ve anchored your biotech strategy in a real-world problem — a patient need, a technical Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

Most biotech startups aren’t killed by bad science. The hardest shift for technical founders isn’t strategy — it’s identity. Every month without a clear strategy delays funding. But in biotech startups, waiting for proof means missing the moment . Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

And strategic consequence. ✅ When biotech founders build stories this way, investors stop asking confusing Turning Investor Questions Into Strategic Advantage Every question a biotech investor asks reveals what You stop translating science into science and start translating it into strategy. ✅ You give your data Strategic Takeaway: Your Story Is the Bridge Between Science and Capital Biotech investors don’t walk Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

When you're spinning out of academia or launching your first science-driven startup, it's easy to default This shift from possible to next is what separates research from strategy. Here is where to start: ✅ Audit your current strategy: Is it written down? Is it actionable? Investors fund movement, not motion. ✅ Bring in strategic support: Book a Timeline Strategy workshop In a focused 1:1 strategy session, you’ll work together to cut through noise, reframe your competitive

. 👉 Q4 exposes the drift that began in Q1 and that biotech leadership never fully confronted. Name and Frame the Pattern: Biotech Leadership Drift Most founders in biotech imagine leadership as steering like: Timelines recalculated as soon as data changes a clear link between milestones and financing strategy . 👉 Biotech leadership isn’t tested by big events. Attila runs focused strategy consultations for biotech founders  who are ready to lead with clarity,

Funding still flows—but only to CEOs who prove they can scale biotech operations  cleanly. 1. Execution Rhythm: Stop Running on Memory Biotech isn’t a science problem—it’s an execution problem.Companies Break the silos, or watch your growth story collapse. 3. Scaling Biotech Operations: Building a Real Company Your science tells them what you’re building. Your scalability narrative tells them if you’ll survive growth.

High-growth SMEs do not slow down at the end of the year. They speed up strategically. strategy in the founder’s head. ✅ This step is where strategy becomes real. Strategy Means Nothing If Your Team Can’t See It Most SME leaders carry a strategy in their heads. Finish Strong and Start Sharper. 👉 Most SME strategies die in silence.